Tokorozawa, Japan

Yuriko Egashira

USPTO Granted Patents = 3 

Average Co-Inventor Count = 3.5

ph-index = 1


Location History:

  • Saitama, JP (2019)
  • Tokorozawa, JP (2020)

Company Filing History:


Years Active: 2019-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Yuriko Egashira: Innovator in Antibody Affinity Enhancement

Introduction

Yuriko Egashira is a notable inventor based in Tokorozawa, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of methods to improve antibody affinity for antigens. With a total of 3 patents to her name, her work has the potential to impact various medical applications.

Latest Patents

One of Yuriko's latest patents is a method for improving the affinity of an antibody for an antigen. This method involves changing at least three amino acid residues in the framework region 3 (FR3) of the antibody to arginine or lysine residues. This modification enhances the antibody's affinity for the antigen compared to its original form. Another significant patent is a method for detecting alpha-fetoprotein (AFP) using a monoclonal antibody that is reactive with a specific glycopeptide.

Career Highlights

Yuriko Egashira is currently employed at Sysmex Corporation, where she continues to innovate in the field of antibody research. Her work is characterized by a strong focus on enhancing the effectiveness of antibodies, which is crucial for diagnostic and therapeutic applications.

Collaborations

Yuriko collaborates with talented colleagues, including Yukiko Higa and Tomofumi Nakada. These partnerships foster a creative environment that drives innovation and advances their shared goals in biotechnology.

Conclusion

Yuriko Egashira's contributions to antibody affinity enhancement and detection methods exemplify her commitment to advancing medical science. Her innovative approaches and collaborative spirit position her as a key figure in the field of biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…